Skip to content
Clinical Trials – home
BulgariaBack to Bulgaria

Clinical trials in Gabrovo – page 12

234 clinical trials in Gabrovo, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gabrovo at a glance
234
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

234 trials in Gabrovo

Open in trial search

Study Comparing BP11 and Omalizumab for Patients with Chronic Spontaneous Urticaria Resistant to H1 Antihistamines

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Curateq Biologics Private Limited

Colitis ulcerative

Not recruiting

Study on Long-Term Safety of Etrasimod Arginine for Patients with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Colitis ulcerative+1

Not recruiting

Study on the Long-Term Effects of TEV-48574 (Duvakitug) for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Hypertriglyceridaemia

Not recruiting

Study to Evaluate Plozasiran for Adults with High Triglycerides

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol in Patients Aged 40-80 with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Vitiligo

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on Rezpegaldesleukin for Treating Moderate-to-Severe Atopic Dermatitis in Adults

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Other cities in Bulgaria

The busiest research cities in the country

All 52 cities in Bulgaria

Clinical research in Gabrovo

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, lung cancer, and bladder cancer. Research encompasses both targeted therapies and combination treatments.

  • Metastatic breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Prostate cancer interventions
  • Bladder cancer treatments

Special emphasis on developing targeted therapies for specific genetic mutations and combinations with immunotherapy.

02 Respiratory Medicine

Comprehensive research into respiratory conditions, with particular focus on chronic diseases and their management through innovative therapeutic approaches.

  • Asthma management studies
  • COPD treatment evaluations
  • Maintenance therapy optimization

Trials evaluate both single and combination therapies for improving lung function and quality of life.

03 Dermatology Studies

Advanced research in chronic skin conditions, investigating new therapeutic options for various dermatological disorders.

  • Plaque psoriasis treatments
  • Atopic dermatitis therapies
  • Long-term safety evaluations

Focus on developing both topical and systemic treatments for moderate to severe cases.

04 Cardiovascular Research

Innovative studies addressing heart conditions and related metabolic disorders, including new approaches to managing cholesterol and heart failure.

  • Heart failure treatments
  • Cholesterol management
  • Hypertriglyceridemia therapies

Emphasis on both preserved and reduced ejection fraction heart failure treatments.

05 Infectious Diseases

Research focusing on viral infections and preventive medicine, including vaccine development and infection management.

  • Influenza vaccine studies
  • Varicella vaccination
  • Urinary tract infection treatments

Special attention to vaccine safety and efficacy in various age groups.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.